Processa Pharmaceuticals filings document formal 8-K and amended 8-K disclosures for a clinical-stage biopharmaceutical issuer. The records cover material events involving licensing and term-sheet matters, Nasdaq listing compliance, executive-officer status changes and compensatory arrangements, and shareholder-vote reporting.
The company's filings also describe capital-structure and charter actions, including amendments to its certificate of incorporation, authorized-share changes, reverse stock split mechanics, common-stock rights and related governance approvals. These disclosures frame Processa's public-company status, equity structure and corporate governance alongside its development-stage pharmaceutical business.
Processa Pharmaceuticals director and officer David Young, President of Research & Development, reported the vesting and distribution of restricted stock units into common stock on January 1, 2026. A total of 49 restricted stock units were converted at an exercise price of $0, resulting in 49 common shares acquired.
Following this transaction, Young holds 8,752 Processa common shares directly. He also has indirect beneficial ownership of common stock, including 1,242 shares through the Young-Plaisance Revocable Trust, 432 shares through family entities, and 742 shares through CorLyst, LLC. The filing describes the event as a distribution of vested restricted shares.
Processa Pharmaceuticals Chief Business - Strategy Officer Patrick Lin reported a small equity transaction. On January 1, 2026, Lin acquired 193 shares of Common Stock at an exercise price of $0 through the conversion of a derivative security, described as a distribution of vested restricted shares.
Following this vesting-related transaction, Lin directly beneficially owned 1,753 shares of Common Stock. In addition, 1,740 shares were held indirectly through the Lin Family Trust Feb 4, 2024, reflecting his combined direct and indirect ownership position in Processa Pharmaceuticals.
Processa Pharmaceuticals, Inc. reported an equity award transaction by Chief Administrative Officer Wendy Guy. On January 1, 2026, 193 restricted stock units converted into 193 shares of common stock at a price of $0 per share, described as a distribution of vested restricted shares. Following the transaction, Guy beneficially owned 1,256 shares of common stock directly and 333 shares indirectly through CorLyst, LLC.
Processa Pharmaceuticals Chief Development Officer Sian Bigora reported an equity award vesting and related share distribution. On January 1, 2026, 249 restricted stock units converted into 249 shares of common stock at an exercise price of $0, described as a distribution of vested restricted shares.
Following this transaction, Bigora beneficially owns 1,604 shares of Processa common stock directly and an additional 267 shares indirectly through CorLyst, LLC. The filing reflects compensation-related share delivery rather than an open‑market purchase or sale.
Processa Pharmaceuticals, Inc. reported that on January 6, 2026 it received written notice from the Nasdaq Stock Market staff that the company has regained compliance with the $1.00 minimum closing bid price requirement for continued listing on the Nasdaq Capital Market under Listing Rule 5550(a)(2). Nasdaq indicated that the bid-price deficiency matter is now closed, meaning the company’s common stock remains eligible to trade on the Nasdaq Capital Market under its existing listing standard.
Processa Pharmaceuticals, Inc. is implementing a 1-for-25 reverse stock split of its common stock, effective as of 5:00 p.m. Eastern Time on December 16, 2025. Starting December 17, 2025, its shares will trade on the Nasdaq Capital Market on a split-adjusted basis under the existing ticker PCSA.
Each block of 25 existing shares will be converted into 1 share, with fractional share amounts rounded up to the nearest whole share rather than paid in cash. The reverse split does not change the $0.0001 par value or the authorized 1,000,000,000 shares of common stock, and it applies uniformly so that stockholders’ relative ownership percentages remain the same. All outstanding options, warrants, restricted stock units and similar securities will be adjusted to reflect the new share count.
Processa Pharmaceuticals (PCSA) filed its Q3 2025 10‑Q, reporting continued operating losses and a going concern warning. Net loss was $3,436,573 for the quarter and $10,204,896 year‑to‑date. Cash and cash equivalents were $6,308,420 as of September 30, 2025. Management says existing cash, plus subsequent warrant proceeds, should fund operations into the first quarter of 2026.
The company raised capital through multiple 2025 transactions, including $4.4 million in January and $6.2 million in June offerings, $1.2 million via an accredited investor sale, and $1.0 million under its ATM, with additional warrant exercises before and after quarter‑end. Processa began implementing a cryptocurrency treasury strategy and held $350,000 in USD‑backed stablecoins at quarter‑end, increasing to $850,000 after. Shares outstanding were 56,644,223 as of November 3, 2025. R&D expense was $1.66 million and G&A was $1.83 million in Q3. The Nasdaq minimum bid price deficiency period was extended through February 2, 2026.
Neal James R, a Director of Processa Pharmaceuticals, Inc. (PCSA), reported issuance of equity awards dated 10/01/2025. The Form 4 shows 100,000 Restricted Stock Units (RSUs) granted with a reported value of $0 and 300,000 stock options granted with a conversion/exercise price of $0.198. Following the reported transactions the reporting person beneficially owns 100,000 RSUs and 300,000 options, each held directly. The RSUs vest one-third on 10/01/2026 and then one-thirty-sixth monthly until fully vested on 10/01/2028. The options vest one-third on the first anniversary of the grant, with the remainder vesting ratably over the next two years. The Form 4 is signed by an attorney-in-fact on behalf of the reporting person and dated 10/03/2025.
Processa Pharmaceuticals, Inc. (PCSA) director Khoso Baluch reported receipt on 10/01/2025 of equity awards: 100,000 Restricted Stock Units and 300,000 stock options with an exercise price of $0.198. Following the grants, the reporting person beneficially owns 100,000 RSUs and 300,000 options directly.
The RSUs vest one-third on 10/01/2026 and then monthly over the following 24 months until fully vested on 10/01/2028. The stock options vest one-third on the first anniversary of the grant, with the remainder vesting ratably over the next two years. The Form 4 was signed by an attorney-in-fact on 10/03/2025.
Geraldine Pannu, a director of Processa Pharmaceuticals, Inc. (PCSA), reported grants on 10/01/2025 consisting of 100,000 restricted stock units (RSUs) and 300,000 stock options with an exercise price of $0.198. The RSUs vest one-third on 10/01/2026 and then monthly over two additional years until fully vested on 10/01/2028. The options vest one-third on the first anniversary of the grant with the remainder vesting ratably over the next two years. Following these grants, Ms. Pannu beneficially owns 100,000 shares represented by the RSUs and has rights to acquire 300,000 shares via options. The Form 4 was signed on 10/03/2025 by an attorney-in-fact on her behalf.